uniQure (NASDAQ:QURE) Shares Gap Up - What's Next?

Key Points

• uniQure shares opened sharply higher, rising from a prior close of $24.83 to $26.22, but later traded at $23.3850, down 3.6%.
• Analyst sentiment is broadly positive: uniQure has an average “Moderate Buy” rating and a consensus price target of $53.25, though ratings range from Strong Buy to Sell.
• Institutional investors own 78.83% of the company, while uniQure continues developing gene therapies, including HEMGENIX for hemophilia B, which is commercialized by CSL Behring.

uniQure N.V. (NASDAQ:QURE - Get Free Report)'s stock price gapped up before the market opened on Monday. The stock had previously closed at $24.83, but opened at $26.22. uniQure shares last traded at $23.3850, with a volume of 1,996,815 shares.

Wall Street Analysts Forecast Growth

QURE has been the topic of several research reports. HC Wainwright reiterated a "buy" rating on shares of uniQure in a report on Tuesday, September 29th. Wall Street Zen lowered uniQure from a "hold" rating to a "sell" rating in a report on Saturday, September 5th. Wolfe Research raised shares of uniQure from a "peer perform" rating to an "outperform" rating and set a $65.00 target price on the stock in a report on Wednesday, July 29th. UBS Group started coverage on shares of uniQure in a report on Thursday, October 15th. They set a "buy" rating and a $48.00 price objective for the company. Finally, William Blair upgraded uniQure to a "strong-buy" rating in a report on Wednesday, September 23rd. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $53.25.

uniQure Stock Down 3.6%

The company has a fifty day moving average of $34.55 and a 200 day moving average of $29.67. The company has a quick ratio of 10.01, a current ratio of 10.01 and a debt-to-equity ratio of 0.15. The company has a market cap of $1.66 billion, a P/E ratio of -5.98 and a beta of 1.14.

Institutional Trading of uniQure

Several large investors have recently added to or reduced their stakes in QURE. Mirae Asset Global Investments Co. Ltd. bought a new stake in uniQure during the 3rd quarter valued at approximately $86,000. China Universal Asset Management Co. Ltd. bought a new position in shares of uniQure during the third quarter valued at approximately $310,000. Maxi Investments CY Ltd purchased a new stake in shares of uniQure during the third quarter valued at about $966,000. IFP Advisors Inc boosted its holdings in uniQure by 18.0% in the third quarter. IFP Advisors Inc now owns 3,280 shares of the biotechnology company's stock worth $79,000 after acquiring an additional 500 shares in the last quarter. Finally, Activest Wealth Management acquired a new stake in uniQure during the 3rd quarter worth about $121,000. 78.83% of the stock is currently owned by institutional investors.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on developing gene therapies for serious and life-threatening diseases. The company uses adeno-associated virus (AAV) vectors and other genetic medicine technologies to deliver therapeutic genes intended to address the underlying causes of disease.

uniQure's best-known product is HEMGENIX, a gene therapy for adults with hemophilia B caused by factor IX deficiency. HEMGENIX was developed by uniQure and is commercialized by CSL Behring under a global licensing agreement.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.